CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized...
Phase 3
•Worcester, Massachusetts, United States and 19 other locations
will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants with multiple...
Phase 1
•Worcester, Massachusetts, United States and 19 other locations
This study will evaluate whether ofatumumab is excreted at quantifiable levels and at which concentrations in breast milk of lactating women with RMS...
Phase 4
•Brookline, Massachusetts, United States and 8 other locations
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...
Phase 3
•Boston, Massachusetts, United States and 73 other locations
of nasal foralumab in patients with non-active secondary progressive multiple sclerosis (SPMS).The primary objectives that this stu...
Phase 2
•Boston, Massachusetts, United States and 4 other locations
(IV) (Part 1) and subcutaneous (SC) (Part 2) doses of RO7121932 and multiple ascending SC (Part 3) doses of RO7121932 in participants with m ...
Phase 1
•Worcester, Massachusetts, United States and 30 other locations
This phase 2a study will research the safety and tolerability of Foralumab, a human anti-CD3 antibody. An antibody is a molecule secreted by the immu...
Phase 2
•Boston, Massachusetts, United States
This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...
Phase 3
•Boston, Massachusetts, United States and 106 other locations
This study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofat...
Phase 4
•Worcester, Massachusetts, United States and 40 other locations
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...
Phase 2
•Worcester, Massachusetts, United States and 48 other locations
Clinical trials
Research sites
Resources
Legal